Clinical Trial Update: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial update reports a medication change for non-responders in a cognitive-behavioral plus pharmacologic treatment approach for binge-eatin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder
• Obesity

Drugs mentioned

• LDX (lisdexamfetamine)

Snippet

Sponsor: Yale University | Conditions: Binge-Eating Disorder, Obesity | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-12-17